Lab-grown brain tissue shows how glioblastoma cells pick where to spread
Original title: Human cortico-vascular assembloids reveal a CELF2-AHNAK-dependent switch from neuronal to endothelial tropism in glioblastoma cells.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done on cells in a lab, not in people. It is a very early step.
This was done in lab-grown tissue and tumor samples, not in people.
The short version
Scientists built a small model of human brain tissue to watch how tumor cells spread.
What was studied. Researchers grew tiny clumps of human brain cells and blood vessel cells, then joined them. They put glioblastoma: A glioma that is given grade 4. Grade 4 is the highest grade there is. The tumor grows fast. Treatment usually starts soon after it is found. It often means surgery, and then radiation and chemotherapy. See the glossary stem cells into this model and watched where the tumor cells went. They also checked tumor samples taken from patients.
What they found. Tumor cells that made a protein called CELF2 moved into the nerve areas, where they harmed nerve cells and damaged the lining of blood vessels. When CELF2 was missing, the cells turned toward blood vessels instead, and this shift needed another protein called AHNAK. Patient tumor samples showed the same pattern, with CELF2 cells sitting in areas that had few blood vessels.
What this means, and what it doesn't
What it could mean: This gives a clue about what steers tumor cells as they spread through the brain. In time, that clue may help scientists look for new ways to slow the spread.
What it doesn't mean: This is not a treatment and it does not mean a cure is close. The work was done in lab-grown tissue and in stored tumor samples. No patient was treated, and no drug was tested. It is early science, far from everyday care, and years of more work would be needed first.
Source: PubMed, August 5, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.